MacroGenics | MGNX - Current Liabilities


MacroGenics reported $95.94M in Current Liabilities for its fiscal quarter ending in March of 2026.





Current Liabilities Change Date
AbbVie USD 42.1B 1.19B Mar/2026
Amgen USD 24.96B 534M Mar/2026
AstraZeneca USD 32.57B 1.95B Mar/2026
Biogen USD 3B 350.5M Mar/2026
Bristol-Myers Squibb USD 19.16B 4.26B Mar/2026
Daiichi Sankyo JPY 778.55B 77.51B Dec/2025
Eli Lilly USD 36.63B 1.41B Mar/2026
Genmab DKK 1.43B 686M Dec/2025
Geron USD 73.57M 40.25M Mar/2026
Gilead Sciences USD 9.48B 2.34B Mar/2026
J&J USD 57.72B 3.59B Mar/2026
Karyopharm Therapeutics USD 92.06M 4.9M Dec/2025
MacroGenics USD 95.94M 52.82M Mar/2026
Merck USD 26.94B 1.38B Mar/2026
Pfizer USD 34.35B 2.64B Mar/2026
Puma Biotechnology USD 82.73M 3.63M Sep/2025
Regeneron Pharmaceuticals USD 5.11B 739.3M Mar/2026
Roche Holding CHF 28B 421M Dec/2025
Xencor USD 73.46M 22.45M Mar/2026